
Encouraging phase I data for Bavarian Nordic’s vaccine candidate against respiratory syncytial virus (RSV) shows that the candidate is on the right path, the Danish biotech company said late this week.
The biotech said that 6 month follow-up data from the phase I trial with its candidate MVA-BN RSV shows the antibody response induced by the vaccine candidate remained at similar levels to what had been reported previously. It is proof that MVA-BN RSV induced a durable immune response lasting at least 6 months; a period spanning a normal RSV season, it believes.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app